ACADIA Pharmaceuticals Inc (ACAD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)

ACAD 25.04

+0.9%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mopgcw	7/22/2007 2:48:52 AM
	Read Replies (1) of 588

Acadia Pharmaceuticals - ACAD-NNM Market Outperform - Price 13.68 on July 16 by Rodman & Renshaw Market cap: $504.4 million. ACAD announced that Allergan will commence an exploratory Phase I clinical study with a small-molecule drug candidate for glaucoma treatment, an undisclosed milestone payment to Acadia...The compound emanates from a discovery made at Acadia... clear validation of ACAD's drug-discovery approach. Reiterate Market Outperform; 19 target.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next